NCT03490032 - 68Ga-PSMA-R2 in Patients With Biochemical Relapse (BR) and Metastatic Prostate Cancer (mPCa) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 23, 2018

Primary Completion Date

August 20, 2019

Study Completion Date

September 13, 2019

Conditions

Prostate Cancer Metastatic

Interventions

DRUG

[68Ga]-PSMA-R2

radio-labelled PSMA ligand

Trial Locations (5)

National Institutes of Health, Warren Grant Magnusen Clinical Center, Bethesda

Johns Hopkins Hospital, Baltimore

Pheonix Molecular Imaging Center, Phoenix

University of California, San Francisco (UCSF), San Francisco

Smilow Cancer Center at Yale New Haven, New Haven